Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man

Neuropsychobiology

Volumn 51, Issue 4, 2005, Pages 226-233

  Passie, Torsten ^a   Karst, Matthias ^a   Wiese, Birgitt ^a   Emrich, Hinderk M ^a   Schneider, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

(S) ketamine; Altered states of consciousness; Attention; Hallucinogens; Ketamine; Memory; N methyl D aspartate antagonists; Schizophrenia

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; ARTICLE; ATTENTION; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; MENTAL DISEASE; MENTAL FUNCTION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; STANDARD; TASK PERFORMANCE;

ADULT; ANALGESICS; ANALYSIS OF VARIANCE; ATTENTION; CONSCIOUSNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; KETAMINE; MALE; NEUROPSYCHOLOGICAL TESTS; NEUROPSYCHOLOGY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; PSYCHOPATHOLOGY; QUESTIONNAIRES; REACTION TIME; SIGNAL DETECTION (PSYCHOLOGY);

EID: 22144448892     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085724     Document Type: Article

References (36)

1. Bunney BG, Bunney WE, Carlsson A: Schizophrenia and glutamate: in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 1205-1214.
2. Krystal JH, Karper LP, Saibyl JP, Freeman GK, Delaney R, Brenner JD, Heninger GR, Bowers MB, Charney DS: Subanesthetic effects of the noncompetetive NMDA antagonist ketamine in Humans. Arch Gen Psychiat 1994;51:199-214.
3. Breier A, Malhotra AK, Pinals DA, Weisenfels NI, Pickar D: Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997;154:805-811.
4. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J: Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology 1997a;7:25-38.
5. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH: The NMDA antagonist model of schizophrenia: Promise and pitfalls. Pharmacopsychiatry 1998;31:104-109.
6. Way WL, Trevor AJ, White PF: Pharmacology of the ketamine enantiomorphs; in Domino EF (ed): Status of Ketamine in Anaesthesiology. Ann Arbor, 1990, pp 101-108.
7. Adams HA: Wirkmechanismen von Ketamin. Anaethesiol Reanimat 1998;23:60-63.
8. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A: NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-307.
9. Oranje B, van Berkel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN: The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 2000;22:293-302.
10. Krystal JH, Bennett A, Abi-Saab D, Belder A, Karper LP, D'Souza DC, Lipschitz D, Abi-Dargham A, Charney DS: Dissociation of ketamine effects on rule acquisition and rule implementation: Possible relevance to NMDA receptor contributions to executive cognitive functions. Biol Psychiatry 2000;47:137-143.
11. Lahti AC, Koffel B, LaPorte D, Tamminga CA: Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19.
12. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A: Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997;17:141-150.
13. Newcomer JW, Krystal JH: NMDA receptor regulation of memory and behavior in humans. Hippocampus 2001;11:529-542.
14. LaPorte DJ, Lahti AC, Koffel B, Tamminga CA: Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. J Psychiatr Res 1996;30:321-330.
15. 18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997b;7:9-24.
16. Overall JE, Gorham DR: Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
17. Dittrich A: Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. Stuttgart, Enke, 1985.
18. Dittrich A: Standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 1998;31:280-284.
19. Benton AL: A visual retention test for clinical use. Arch Neurol Psychol 1945;59:273-291.
20. Kuzis G, Sabe L, Tiberti C, Merello M, Leiguarda R, Starkstein SE: Explicit and implicit learning in patients with Alzheimers disease and Parkinson disease with dementia. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:265-269.
21. Müller-Vahl KR, Koblenz A, Jobges M, Kolbe H, Emrich HM, Schneider U: Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 2001;34:19-24.
22. Zimmermann F, Fimm B: Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Freiburg, Psychologisches Institut der Universität Freiburg, 1989.
23. Hasse-Sander I, Gross G, Huber G, Peters S, Schuttler R: Examinations by psychological tests in basic stages and pure residual syndromes of schizophrenic diseases (in German). Arch Psychiat Nervenkr 1982;231:235-249.
24. Schneider U, Bevilacqua C, Jacobs R, Karst M, Dietrich DE, Becker H, Muller-Vahl KR, Seeland I, Gielsdorf D, Schedlowski M, Emrich HM: Effects of fentanyl and low doses of alcohol on neuropsychological performance in healthy subjects. Neuropsychobiology 1999;39:38-43.
25. Domino EF, Chodoff P, Corssen G: Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965;6:279-291.
26. Dittrich A, Arx S, Staub S: International study on altered states of consciousness (ISASC): Summary of the results. German J Psychol 1985;9:319-339.
27. Bowdle TA, Radant AD, Cowley DS, Karash ED, Strassman RS, Roy-Byrne PP: Psychedelic effects of ketamine in healthy volunteers: Relationship to steady state plasma concentrations. Anesthesiology 1998;88:82-88.
28. Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer A Ml Kunert H J, Sass H: Hallucinogenic drug induced states resemble acute endogenous psychoses: Results of an empirical study. Eur Psychiatry 1998;13:399-406.
29. Corssen G, Oget S, Reed PC: Psychic Effects of Ketamine. Anesth Analg 1971;50:397-401.
30. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
31. Oye I, Hustveit O, Moberg ER, Pausen O, Skoglund LA: The chiral forms of ketamine as probes for NMDA receptor function in humans; in Kameyama T, Nabeshima T, Domino EF (eds): NMDA Receptor Related Agents: Biochemistry, Pharmacology, and Behavior. Ann Arbor, NPP Books, 1991, pp 381-389.
32. Oye I, Paulsen O, Maurset A: Effects of ketamine on sensory perception: Evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992;260:1209-1213.
33. Harris JA, Biersner RJ, Edwards D, Bailey LW: Attention, learning and personality during ketamine emergence: A pilot study. Anesth Analg 1975;54:169-174.
34. Ghonheim MM, Hinrichs JV, Mewaldt SP, Petersen RC: Ketamine: Behavioral effects of subanesthetic doses. J Clin Psychopharmacol 1985;5:70-77.
35. Vollenweider FX, Geyer MA: Systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull 2001;15;56:495-507.
36. Tamlyn D, McKenna PJ, Mortimer AM, Lund CE, Hammond S, Baddeley AD: Memory impairment in schizophrenia: Its extent, affiliations and neuropsychological character. Psychol Med 1992;22:101-115.